

Key Information Document

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

Product

The product is a limited partnership interest in Wellington Partners Life Sciences VI GmbH & Co. KG (the "Fund"), produced by Wellington Partners Life Science Venture Capital Management GmbH as managing limited partner (the "Managing Limited Partner").

Manufacturer of the Product

Wellington Partners Life Science Venture Capital Management GmbH

Competent Authority: Die Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin), in relation to this KID

Production date of the KID: 01.07.2022

You are about to subscribe for a product that is not simple and may be difficult to understand.

1. What is this product?

Type

This product is a limited partnership interest issued under German law.

Term

There is a minimum period in which the Fund will be operating. This is a period of 10 years after the first closing of the subscription period with the option to extend this period for up to two years. An investor, as a matter of general principle, cannot cancel its investment in the Fund without cause.


Objectives

The Fund is to carry on the business of an investor and, in particular, of identifying, negotiating, making, monitoring and realising equity and equity-related investments in the early stages of companies that are developing and/or marketing innovative therapeutics, diagnostics, medical technology, digital health and industrial biotechnology venture products with high-growth potential and to carry out all functions and acts in connection therewith.

The Fund is an externally managed closed-ended special alternative investment fund (*Spezial-AIF*) within the meaning of the KAGB and has appointed the Managing Limited Partner as its external alternative investment fund manager ("*External AIFM*" - externe Kapitalverwaltungsgesellschaft) within the meaning of Sec. 17 para 2 no. 1 KAGB.

2. What are the risks and what could I receive in return?

Risk indicator¹



This risk indicator is based on the assumption that you will hold the product for 10 years after the first closing of the subscription period.

If you sell your investment at an earlier point in time, the actual risk may deviate considerably from the above indication and you may receive a lower amount in return. A sale is only permissible with the prior consent of the Managing Limited Partner and may be withheld at the Managing Limited Partner's sole discretion.

The overall risk indicator helps you to assess the risk associated with this product compared to other products. It shows the level of probability that you may lose money when investing in this product due to market developments or because we are unable for other reasons to select attractive investments or monetise the relevant investments at attractive terms.

We have classified this product on a scale of 1 to 7 as risk category 6, i.e. the category entailing the second highest level of risk. The risk of potential losses resulting from future performance is classified as high.

¹ Summary Risk Indicator to be completed following methodology for calculating MRM (market risk measure) and CRM (credit risk measure) set out in Annex III, RTS (2017/653) and ESA paper on risk and reward calculations. (An indicative figure has been shaded in but this will need to be updated once methodology has been completed).

In the case of unfavourable market conditions, the Fund's performance is likely to be adversely affected. This product does not involve any hedging against future market developments, which means that you may lose all or part of the capital invested. If we are unable to pay the amount to which you have paid in, you may lose all capital invested.

Performance Scenarios²

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The scenarios shown are illustrations based on results from the past and on certain assumptions. Markets could develop very differently in the future.

Recommended holding periods: 10 years (Minimum holding)

Assumed Investment for illustrative purposes: EUR 10,000

Investment EUR 10,000 Scenarios		If you redeem after 1 year	If you redeem after 5 years	If you redeem after 10 years
Minimum	There is no minimum guaranteed return. You could lose part or all of your investment.			
Stress	What you might get back after costs	9,772	8,933	3,254
	Average return each year	-2.3% ³ p.a.	-6.7 % p.a.	-22.4 % p.a.
Unfavourable	What you might get back after costs	9,772	8,933	11,003
	Average return each year	-2.3% p.a.	-6.7 % p.a.	2.3 % p.a.
Moderate	What you might get back after costs	9,772	8,933	19,804
	Average return each year	-2.3% p.a.	-6., % p.a.	18.2 % p.a.
Favourable	What you might get back after costs	9,772	8,933	26,203
	Average return each year	-2.3% p.a.	-6.7 % p.a.	26.6 %p.a.

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

The stress scenario shows what you might get back in extreme market circumstances.

The scenarios shown represent possible outcomes based on simulations.

3. What happens if the Fund is unable to pay out?

As a consequence, you do not receive a return of your invested amount. A protection scheme against payment defaults does not exist. There is no guarantee regarding the future performance of the Fund.

There will be no insurance policy in relation to the product.

4. What are the costs?

The person advising or offering you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year you would get back the amount that you invested (0 % annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario
- EUR 10,000 is invested

Investment: EUR [-]			
Scenario	If you redeem after 1 year	If you redeem after 5 years	If you redeem after recommended holding period
Total costs	EUR 228	EUR 1,067	EUR 4,196
Annual cost impact (*), (**)	2.3 % p.a.	6.7 % p.a.	8.3 % p.a.

² Performance scenarios to follow methodology set out in Annex V, RTS. Percentages to be completed.

³ Ein gängiges KID geht davon aus, dass die durchschnittliche Rendite als der Marktwert des Produkts in jedem Szenario geteilt durch den Nennwert berechnet wird.

(*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 26.4 % before costs and 18.2 % after costs.

(**) The Fund does not permit redemptions of your Investment.

Composition of Costs

This table shows the impact on return per year ⁴		
One-off costs upon entry or exit		If you exit after recommended holding period
Entry costs	The impact of the costs you pay when entering your investment. This is the most you will pay and you could pay less	20 EUR (***)
Exit costs	No costs incur if you exit your investment when it matures.	Not applicable
Ongoing costs taken each year		
Management fees and other administrative or operating costs	2% p.a. on your investment (for total commitments up to €250m) and 1.5% p.a. on your investment (for total commitments above €250m); after expiry of investment period, 85% of amount calculated in respect of preceding accounting period.	20 EUR (***)
Transaction costs	[•]% of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	49 EUR
Incidental costs taken under specific conditions		
Performance fees and carried interest	The impact of carried interests. We are generally entitled to 20% of profits when the investment has performed better than an IRR of 6%. The actual amount will vary depending on how well your investment performs.	0 EUR (***)

(***) The actual final value may not be determined due to the dynamic contractual methodology.

5. How long should I hold it and can I take money out early?

Minimum holding period: 10 years

The minimum holding period is 10 years after the first closing of the subscription period. If the term is extended by up to two years, the holding period may be longer than 10 years. Subject to the possible extension of the term by up to two years, the closed-end Fund will end on the 10th anniversary of the first closing of the subscription period. Any transfer of a limited partner's interest in the Fund requires the Managing Limited Partner's prior written consent.

For German individuals only: regarding your investment in the Fund. Please see the information on the revocation right in the subscription documents. Termination of your investment in the Fund is possible only in the mandatory cases prescribed by law. Therefore, you may not be able to terminate your investment prior to expiry of the minimum holding period.

6. How can I complain?

Any complaint regarding the person advising on, or selling, the product can be submitted directly to that person. Any complaint regarding the product or the conduct of the Managing Limited Partner should be addressed in writing to the Managing Limited Partner at Türkenstrasse 5, 80333 Munich, Germany.

7. Other relevant information

Any additional information in relation to the product and in particular the partnership agreement and the subscription documents are published on the Managing Limited Partner's website Wellington Partners Life Science Venture Capital Management GmbH, in accordance with legal requirements. In order to obtain more detailed information, in particular, details of the structure of and risks associated with an investment in the product, we recommend you read these documents.

⁴ Guidance on completion of the costs table is provided in Article 5 and Annex VI, RTS.